Tasuku Fujiwara
Papers
1
Total Citations
4
H-Index
1
About
Dr. Tasuku Fujiwara is a leading urologic oncologist whose research focuses on optimizing treatment strategies for high-risk and very high-risk prostate cancer, particularly through neoadjuvant chemohormonal therapy and robotic surgery. His major contributions center on evaluating the safety and efficacy of combining degarelix acetate with low-dose estramustine phosphate prior to robot-assisted radical prostatectomy. In a pivotal 2024 study involving 187 patients, Dr. Fujiwara demonstrated that dose compliance with estramustine phosphate in this neoadjuvant regimen is a significant predictor of biochemical recurrence, offering a practical biomarker for treatment success. This work, which has already garnered 4 citations, provides critical insights into personalizing therapy for patients with aggressive disease. Dr. Fujiwara’s research bridges the gap between pharmacologic compliance and surgical outcomes, underscoring the importance of adherence in achieving long-term cancer control. His findings are shaping clinical decision-making for very high-risk prostate cancer, making him a key figure in advancing multimodal treatment approaches that improve patient prognosis.
Research Focus
Key Achievements
Top Papers
- 1